Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | BCHE | P06276 | 4/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20175934 | 0.99 | BCHE (0.45) | MAPTBCHEACHEHTR1AMEN1 | |
| SCHEMBL20175939 | 0.90 | MAPT (0.47) | MAPTBCHEACHEHTR1AMEN1 | |
| SCHEMBL20175943 | 0.90 | MAPT (0.47) | MAPTBCHEACHEHTR1AMEN1 | |
| SCHEMBL20180883 | 0.85 | BCHE (0.43) | BCHEACHEHTR1AHSD17B10HSPA5 | |
| SCHEMBL20175931 | 0.85 | ACHE (0.52) | MAPTBCHEACHEHSP90AA1 | |
| SCHEMBL20175935 | 0.85 | BCHE (0.46) | MAPTBCHEACHEHTR1AMEN1 | |
| SCHEMBL20175937 | 0.83 | BCHE (0.40) | MAPTBCHEACHEHTR1AMEN1 | |
| SCHEMBL20175945 | 0.82 | BCHE (0.42) | MAPTBCHEACHEHTR1AMEN1 | |
| SCHEMBL20175938 | 0.82 | BCHE (0.42) | MAPTBCHEACHEMEN1KMT2A | |
| SCHEMBL20175940 | 0.81 | BCHE (0.41) | MAPTBCHEACHEHTR1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140581-A1 | METABOLICALLY PROGRAMMED METAL CHELATORS AND USES THEREOF | FECH, SLC19A1, SLC40A1 | MAPT 3805/4885BCHE 1142/4885ACHE 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.